Background and aims To develop and validate a new index, SLEDAI-2K Glucocorticoids Index (SGI), to accurately describe disease activity while accounting for GC doses.
Methods Phase 1: Identification of patient scenarios followed in a longitudinal cohort. Phase 2: Equation’s derivation explaining the association between SLEDAI-2K and GC dose while using physician global assessment (PGA) as Gold Standard. Phase 3: Validation of SGI against SLEDAI-2K in active patients.
Scenarios were identified using the top 13 organ involvement combinations, then patients were grouped into 7 categories based on GC dose and 10 patients per category were selected. Scenario information included: SLEDAI-2K score, organ involvement combination and GC dose.
3 rheumatologists ranked disease activity with PGA. An independent cohort was used for the validation in phase 3. We hypothesised that in patients with improvement/worsening by SLEDAI-2K, the change in SLEDAI-2K and SGI will correlate.
Results Scenario development is summarised in table 1. 131 scenarios were ranked by 3 rheumatologists leading to 393 records. Perfect LS agreement was achieved; ICC (2, k) of 0.89 (95% CI: 0.83, 0.89). A quadratic linear regression model relating GC and SLEDAI-2K was structured; SGI score=SLEDAI-2K score+[3.65+0.29*GC–0.0027(GC*GC)]. The weight score of GC doses was derived (Table 2). Construct Validity: 109 of the 158 patients improved, 38 remained unchanged, 11 worsened. SLEDAI-2K and SGI correlated highly (r=0.87) and changed in the same direction in patients with improvement/worsening proving the validity of SGI.
Conclusions We developed and validated a novel lupus disease activity index, SGI, that describes disease activity while accounting for GC dose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.